Unlike other EZH2 inhibitors, which are limited to certain hematological malignancies, DZNep has a wide range of therapeutic effects in various tumors, such as breast cancer 6, non-small cell lung cancer 44, and pancreatic cancer 45. This evidence concerns the gene EZH2 and hematologic disorder.